

A3
Amend.

X_4 is an amino acid selected from the group consisting of I, L, and V;
 X_5 is an amino acid selected from the group consisting of I, L, and V;
 X_6 is an amino acid selected from the group consisting of M;
 X_7 is an amino acid selected from the group consisting of D, E, H, K, and R; and
 X_8 is hydrogen, a carboxyl-terminal blocking group, or one to twenty amino acid residues, and an instructional material for using [said] the kit.

A4

22. (Amended) The composition of claim 21, wherein [said] the thrombolytic agent is selected from the group consisting of tissue plasminogen activator, streptokinase, urokinase, the streptokinase derivative and staphylokinase.

A5

24. (Amended) The composition of claim 23, wherein [said] the anti-coagulating agent is selected from the group consisting of an agent which inhibits platelet function, and agent which inhibits the activity of thrombin, and agent which promotes the activity of activated protein kinase C, an anti-thrombin III agent, and a tissue factor pathway inhibitor.

Remarks

The specification has been amended simply to identify the applications to which the present application claims priority and to insert SEQ ID NO: designations.

Claims 5-20, 22, and 24 have been amended simply to replace the word "said" with the synonym "the", in order to improve the readability of the claims without altering their meaning.

A favorable office action on the merits is respectfully requested at the earliest possible time.

Respectfully submitted,

April 6, 2000
(Date)

By:

DOUGLAS CINES, et al.

GARY D. COLBY, Ph.D., J.D.

Registration No. 40,961

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

One Commerce Square

2005 Market Street - Suite 2200

Philadelphia, PA 19103

Telephone: (215) 965-1200

Direct Dial: (215) 965-1285

Facsimile: (215) 965-1210

E-Mail: gcolby@akingump.com